Progyny, Inc. $PGNY Holdings Raised by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its stake in Progyny, Inc. (NASDAQ:PGNY) by 68.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 82,198 shares of the company’s stock after purchasing an additional 33,380 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Progyny were worth $1,396,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. California State Teachers Retirement System lifted its stake in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares in the last quarter. Teza Capital Management LLC raised its holdings in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after acquiring an additional 516 shares during the period. Aristides Capital LLC raised its holdings in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares during the period. Oxford Asset Management LLP lifted its position in shares of Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Progyny by 3.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,202 shares of the company’s stock valued at $493,000 after acquiring an additional 637 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on shares of Progyny from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citigroup restated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Citizens Jmp lifted their price target on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a report on Monday, May 11th. Finally, Truist Financial lifted their price target on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Insider Activity at Progyny

In related news, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the sale, the director directly owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. This represents a 27.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Melissa B. Cummings sold 9,578 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total transaction of $239,450.00. Following the sale, the chief operating officer owned 73,371 shares of the company’s stock, valued at $1,834,275. This trade represents a 11.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 36,916 shares of company stock valued at $939,875. Insiders own 9.90% of the company’s stock.

Progyny Price Performance

Shares of Progyny stock opened at $31.48 on Wednesday. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 40.88, a P/E/G ratio of 2.50 and a beta of 1.01. The stock has a 50-day simple moving average of $28.82 and a 200-day simple moving average of $23.31. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $33.06.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. During the same quarter last year, the firm earned $0.17 earnings per share. The company’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny declared that its board has approved a stock buyback plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.